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Abstract
Objective Previous studies demonstrated that mequitazine
produces mild sedation after single doses.
Its enantiomer, l-mequitazine, has a stronger potency for
the H1 receptor. The aim of the current study was to assess
the effects of l-mequitazine and mequitazine, alone and with
alcohol, on driving.
Methods Twenty-five healthy volunteers were treated with l-
mequitazine 2.5, 5.0 and 10mg,mequitazine 10mg and placebo,
alone and in combination with alcohol in a double-blind cross-
over design. Driving performance was assessed using the stan-
dardized highway driving test in normal traffic. Its primary mea-
sure is the Standard Deviation of the Lateral Position (SDLP).
Secondary measures consisted of an auditory word learning test
during driving, and subjective measures of driving performance.
Results L-mequitazine 2.5 and 5.0 mg showed no effect on
SDLP in the highway driving test, while SDLP significantly
increased after l-mequitazine 10 mg (alone +1.59 cm; with
alcohol +1.41 cm) and mequitazine 10 mg (with alcohol
+1.17 cm). Alcohol significantly impaired all performance
measures (SDLP +2.63 cm) but did not interact with the ef-
fects of treatment. Subjective measures indicated that partici-
pants were aware of the impairing effects of alcohol, but not of
l-mequitazine and mequitazine.
Conclusion L-mequitazine can be considered safe to drive in
dosages of 2.5 and 5.0 mg. L-mequitazine 10 mg led to mild
driving impairment. Alcohol impaired all performance mea-
sures and added to the effects of l-mequitazine and
mequitazine.
Keywords Antihistamine . Alcohol . L-mequitazine .
Mequitazine . Highway driving test
Introduction
In the general population, the prevalence of allergic rhinitis
(AR), one of the most common chronic diseases, is 20–30 %
(Nathan et al., 1997; Steerenberg et al., 2000). Untreated al-
lergic conditions do not only affect a patient’s health, but also
have a negative effect on cognitive functioning (Vuurman
et al., 1993), quality of life (Kremer et al., 2002; Meltzer,
2001; Wallace et al., 2008) and driving performance
(Vuurman et al., 2014). Antihistamines are the most common-
ly used pharmacotherapeutic option for treatment of AR.
These medicinal drugs cause a relief of symptoms by antago-
nizing peripheral histamine 1 (H1) receptors. However, anti-
histamines can also cross the blood-brain barrier and block H1
receptors in the brain (Simons et al., 2011). Central H1 recep-
tors are implicated in the maintenance of wakefulness (España
et al., 2011). Consequently, H1 antagonists can also produce
sedation, fatigue and associated performance impairment,
which affects daytime functioning such as driving a car. This
in turn leads to an increased risk for occupational injuries and
traffic accidents (Gilmore et al., 1996; Nolen, 1997; O’Hanlon
et al., 1995).
Sedation is of primary concern when considering the
adverse effects of antihistamines. Older, first-generation
antihistamines easily penetrate the blood-brain barrier
and have shown to significantly impair performance in
psychomotor and driving tests (McDonald et al., 2008).
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Newer, second-generation antihistamines penetrate the
brain to a lower extent, due to their physico-chemical
properties (Passalacqua et al., 1996; Tashiro et al.,
2002). Therefore, these produce minor or no impairment
on tests measuring memory, attention, psychomotor per-
formance (Kay and Harris, 1999) and on-the-road driv-
ing, when given in the recommended dose (Isomura
et al., 2014; Theunissen et al., 2009).
Mequitazine is a second-generation antihistamine with
relatively high affinity for muscarinic receptors
(Devillier et al., 2015; Kubo et al., 1987). Its effects
on driving performance have been assessed in two stud-
ies with healthy volunteers (Theunissen et al., 2006;
Theunissen et al., 2004). Dose-dependent driving im-
pairment was found after mequitazine 5, 10 and
15 mg (Theunissen et al., 2004). A follow-up study
with repeated doses of mequitazine 10 mg demonstrated
mild driving impairment after the first dose, which dis-
appeared within 8 days of dosing (Theunissen et al.,
2006). It was concluded that mequitazine leads to mild
impairing effects, compared to other second-generation
antihistamines.
Mequitazine is a racemic mixture that comprises of two
enantiomers, l-mequitazine (V0114) and d-mequitazine
(V0162) (Devillier et al., 2015; Gauthier et al., 2014; Latil
et al., 2007). The antihistaminergic activity mainly resides in
the S-enantiomer, l-mequitazine, whereas the anticholinergic
activity mainly resides in the D-enantiomer. In vitro binding
studies have shown that the affinity of l-mequitazine for H1
receptors is approximately ten times higher and to muscarinic
receptors ten times lower, compared to d-mequitazine
(Heusler et al., 2015; Neliat, 2004). This binding profile could
result in an increase of antihistamine activity and a decrease of
anticholinergic side effects for l-mequitazine as compared to
mequitazine.
Sedating antihistamines may potentiate the impairing
effects of alcohol (Barbanoj et al., 2006; Hindmarch and
Bhatti, 1987). Therefore, regulatory warnings concerning
the combined use of these medicinal drugs and alcohol
on operation of automobiles and other potentially dan-
gerous machinery are applied to all first-generation an-
tihistamines. Second-generation antihistamines, however,
have not been found to potentiate the effects of alcohol
(Vermeeren and O’Hanlon, 1998; Vermeeren et al.,
2002a). Therefore, regulatory warnings concerning use
of alcohol and driving are waived for these drugs
(McDonald et al., 2008).
The aim of the present studywas to assess the effects of single
doses of 2.5, 5.0 and 10 mg l-mequitazine, alone and with alco-
hol, on highway driving and cognition. Effects of l-mequitazine
and mequitazine 10 mg were compared to those of placebo.
Performance was assessed using a standardized highway driving
test and an auditory word learning test during driving.
Methods
Participants
Healthy male and female volunteers (age range 21–45 years)
were recruited via poster advertisement and advertisements in
local newspapers.
Participants were required to be in good health as con-
firmed by a medical history questionnaire, physical examina-
tion, a 12-lead electrocardiogram (ECG), blood chemistry and
haematology and urinalysis. In addition, participants could
only enrol when they possessed a valid driving licence for
more than 3 years, had an average driving experience of at
least 5000 km per year and a bodymass index within the range
of 19 to 30 kg/m2.
Volunteers were excluded for any of the following: preg-
nancy or lactation; history of severe physical or mental disor-
ders, alcoholism or drug abuse; use of systemic medication
within the previous month, except oral contraceptives; blood
donation or participation in any other clinical trial within the
previous 3 months; excessive caffeine use (>six standard units
a day), mild smoking (>four cigarettes a day) or overcon-
sumption of alcohol (>21 standard units a week) and total
alcohol abstinence. In addition, cytochrome P450 CYP 2D6
slow metabolizers, as determined by a dextromethorphan test,
were excluded from the study to avoid carry-over effects due
to residual plasma concentrations or a dramatic increase of the
washout periods.
Participants agreed not to use drugs of abuse or systemic
medication (except oral contraceptives, aspirin and acetamin-
ophen) from 2 weeks before treatment days until their com-
pletion. They had to refrain from smoking and/or consuming
alcohol from the time of arrival at the site during treatment
days until the completion of the testing day. In addition, alco-
holic drinks, grapefruit juice and grapefruit were not permitted
from 24 h before arrival. Caffeine was limited to one cup of tea
at breakfast on treatment days.
The study was approved by the Ethics Review Committee
of Maastricht University and the Academic Hospital
Maastricht, and was conducted in accordance with Good
Clinical Practices (CPMP/ICH/135/95) and with the code of
ethics on human experimentation established by the
Declaration of Helsinki (1964) and subsequent amendments.
Written informed consent was obtained from each participant
before enrolment.
Study design and drug/alcohol administration
The study followed a randomized, double-blind, placebo con-
trolled, five-period crossover design. Treatments were single
oral doses of l-mequitazine 2.5, 5.0 and 10 mg, mequitazine
10 mg and placebo, alone and with alcohol. Medication was
supplied in identical-appearing gelatine capsules. Treatments
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were administrated on five testing days, separated by washout
periods of at least 7 days. On each treatment day, participants
performed two driving tests. The first driving test was com-
pleted after drug or placebo treatment alone, and the second
driving test was completed after an additional alcohol chal-
lenge. Alcohol administration always occurred after comple-
tion of the first driving test. Drug and placebo orders were
randomly assigned from those residing in five, 5 × 5
Williams Squares.
The alcohol dosing regimen was developed to achieve and
sustain a blood alcohol concentration (BAC) just under the
local legal limit for drivers (i.e. 0.5 mg/ml) at the scheduled
start of the second driving test. This normally required the
administration of three weight and gender-calibrated doses
of alcohol (0.23, 0.14, 0.14 mg/kg for males and 0.21, 0.13,
0.13 mg/kg for females) at 15-min intervals. Ethyl alcohol
(96 %) was mixed with orange juice. The individual BAC
was estimated from concentrations in expired alveolar using
a Lion Alcoholmeter® SD-400 (Lion Laboratories Ltd., UK).
Participants failing to achieve a BAC of 0.45 mg/ml after 1 h
were given an additional dose of alcohol (0.05 mg/kg).
Assessments
Highway driving test In the standardized highway driving
test (O’Hanlon, 1984), participants drive a specially instru-
mented car over a 100-km (61 miles) primary highway circuit
accompanied by a licenced driving instructor having access to
dual controls. The participant’s task is to maintain a constant
speed of 95 km/h (58 mph) and a steady lateral position be-
tween the delineated boundaries of the slower right traffic
lane. The vehicle’s speed and lateral position relative to the
left lane delineation is continuously recorded. These signals
are digitally sampled at 4 Hz and edited offline to remove data
recorded during overtaking manoeuvres or disturbances
caused by roadway or traffic situations. The remaining data
yields the standard deviation of lateral position and speed for
each successive 5-km segment and, as the square root of
pooled variance over all segments, for the test as a whole.
The primary outcome variable is the Standard Deviation of
Lateral Position (SDLP, in cm) which is a measure of road
tracking error, or ‘weaving’. The clinical relevance of perfor-
mance changes in the highway driving test have previously
been determined by establishing the relationship between
blood alcohol concentration (BAC) and SDLP (Louwerens
et al., 1987). An average increase in SDLP, compared to pla-
cebo, of +2.4 cm is comparable to driving under the influence
of a BAC of 0.5 mg/ml and from that point onwards associ-
ated with a significant higher risk of traffic accidents
(Borkenstein et al., 1974). The secondary outcome variable
is the Standard Deviation of Speed (SDSP), which is an index
of the ability to maintain a constant speed. The highway driv-
ing test has been proven sensitive to many sedating drugs and
alcohol in blood concentrations as low as 0.35 mg/ml
(Vermeeren et al., 2002a; Vuurman et al., 1996).
Auditory word learning test During the driving test, partic-
ipants performed an Auditory Word Learning Test (AWLT,
adapted from (Rey, 1964)) to assess the effects on declarative
episodic memory. In this test, participants were presented a
series of 15 monosyllabic nouns through a loudspeaker in
the car at a rate of one per 2 s. Immediately thereafter, they
were required to verbally recall as many words as possible.
The same series was repeated on two more trials, and the
words recalled were recorded for offline scoring using a voice
recorder. The sum of the number of words correctly recalled
on the three trials was the Immediate Recall score. After a 20-
min delay, participants were required to recall again as many
words as possible without prompting. The number correctly
recalled was the Delayed Recall score. Segment of the high-
way driving test, in which participants performed the AWLT,
were removed during offline editing.
Subjective evaluations Subjective evaluations of alertness
and driving quality were assessed using a series of visual
analogue scales (100 mm). Participants rated their expected
driving impairment and completed a 16-item mood scale from
which one factor was derived: alertness (Bond et al., 1974).
Immediately upon conclusion of both driving tests, partici-
pants rated the quality of their driving performance.
Procedure
All participants were individually familiarized with the tests
and procedures and rehearsed the driving test within a week
before the first treatment day. On treatment days, participants
were interviewed to verify eligibility and occurrence of ad-
verse events since the last visit. They ingested their medica-
tion in the presence of an investigator at 8 am. They were
required to fast from 3 h before until 1 h after ingestion to
keep absorption rate and tmax before the driving tests constant.
At 9 am, a standardized breakfast was served, and a light
brunch at 12 am. All subjects conducted two successive high-
way driving tests on each testing day. The first test started at
1 pm (i.e. 5 h after drug or placebo treatment), and the second
test started at 3 pm, (i.e. 7 h after drug or placebo administra-
tion and 0.5 h after additional alcohol consumption). Upon
completion of the second driving test, participants were
transported home. An overview of a testing day is given in
Figure 1.
Statistical analysis
A power calculation for repeated measures revealed that a
sample of 25 participants resulted in a power of 99.9 % to
detect a clinically relevant difference of 2.4 cm in SDLP
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between drug and placebo conditions, assuming an alpha of
0.05, a test-retest reliability for SDLP of 0.8 (Verster et al.,
2011), an effect size of 0.81 and a within-subjects SD of
2.97 cm (Theunissen et al., 2013).
All measures were analyzed using general linear model
(GLM) repeated measures. The model included two factors:
Treatment (5 levels) and Alcohol (2 levels). Main effects of
Treatment or Alcohol were further analysed by four drug-
placebo contrasts. These simple contrasts were corrected with
the step-down Holm-Bonferroni method (Holm, 1979). In ad-
dition, interaction effects of Treatment × Alcohol were
assessed by using GLM repeated measures with both factors
included. For each performance parameter, only participants
with complete data sets were entered in the analysis. All sta-
tistical analyses were conducted by using the Statistical
Package for the Social Sciences for Windows (version
21.0.01., SPSS Inc., Chicago, IL, USA).
Results
A total of 31 volunteers were enrolled for this study. One with-
drew after the first treatment period for reasons unrelated to the
study, and five had to be replaced due to protocol violations of
treatment orders. Twenty-five participants (12males, 13 females)
completed the study as planned. Their mean age was
33.4 ± 8.9 years. The men’s height and weight were
184 ± 7 cm and 78 ± 8 kg, and the women’s, 166 ± 6 cm and
67 ± 8 kg. Participants drove on average 12.756 ± 7909 km/year.
Missing data and terminated driving tests
In total, eight out of 250 driving tests were not completed
(3.2 %) because the driving instructor or the participant indi-
cated that it was unsafe to continue. The driving instructor
terminated five tests, one test after use of l-mequitazine
10 mg alone and four tests after use of alcohol (all of female
participants), of which one in combination with l-mequitazine
2.5 mg, one in combination with l-mequitazine 5 mg and two
in combination with l-mequitazine 10 mg. One participant
(female) requested that the driving test be stopped prematurely
after use of l-mequitazine 5 mg combined with alcohol. Two
participants did not start the driving test after l-mequitazine
10 mg combined with alcohol: one male participant due to
nausea, and one female participant because the instructor
had terminated her driving test after use of the drug alone.
As a result, performance data from two participants are miss-
ing for l-mequitazine 10 mg combined with alcohol. For the
six prematurely terminated tests, SDLP and SDSP scores were
calculated from data recorded until termination.
Blood alcohol concentrations
Alcohol challenges resulted in overall mean (±SD) blood al-
cohol concentrations (BACs) of 0.45 ± 0.09 mg/ml at the start
of the second driving test, which declined to 0.30 ± 0.08 mg/ml
at the conclusion of the driving test. Mean BACs measured in
the placebo, l-mequitazine 2.5, 5.0 and 10 mg and mequitazine
10 mg conditions were 0.45, 0.48, 0.45, 0.47 and 0.43 mg/ml at
the start of the second driving, and 0.31, 0.28, 0.29, 0.32 and
0.29 mg/ml at the end of the driving test, respectively. No
significant differences were found in BACs between treatment
conditions.
Highway driving test
Analysis showed significant effects of Treatment (F4.88 = 4.30,
p = 0.007) and Alcohol (F1.22 = 55.56, p < 0.001), on SDLP, but
no significant interaction effect between Treatment × Alcohol
(see Table 1). Mean (95 % CI) increases in SDLP after l-
mequitazine 2.5, 5.0 and 10 mg, and mequitazine 10 mg alone,
compared to placebo alone were 0.16 (−0.68; +1.01), 0.54
(−0.25; +1.33), 1.59 (+0.87; +2.32) and 0.33 (−0.37;
+1.03) cm, respectively. Contrasts analysis showed that the effect
of l-mequitazine 10mg alone was highly significant compared to
placebo (p < 0.001). Other simple contrasts of drug-placebo con-
ditions were not significant.
Alcohol significantly increased SDLP in all treatment con-
ditions. Simple contrast analysis showed an overall mean
(95 % CI) increase in SDLP of 2.54 cm (+1.99, +3.36) (see
Fig. 2).
Sub. Ev. Sub. Ev. 
+ 0:00
+ 1:00
+ 4:00
+ 5:00
+ 8:15
+ 6:15
+ 6:30
+ 7:00
+ 5:30
+ 7:30
+ 0:00
+ 0:30
+ 1:00
+ 1:45
AWLT Breakfast 
Treatment 
administration 
Highway driving test 
 (without alcohol) 
Highway driving test 
 (with alcohol) 
Alcohol 
challenge 
AWLT Brunch 
Fig. 1 Overview testing day.
Time (in hours) is displayed for
post-treatment (upper row) and
post- alcohol (lower row)
administration. Sub.Ev. subjective
evaluations, AWLT auditory word
learning task
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Table 1 Mean (+SE) scores of the highway driving test, the AWLT and subjective measures per treatment, alone and with alcohol and summary of
overall effects of treatment, alcohol and treatment × alcohol
Highway driving AWLT Driving quality
SDLP SDSP Immediate Delayed Pre-test Post-test Alertness
No alcohol
Plac 16.86 ± 0.56 2.15 ± 0.13 27.20 ± 1.24 8.62 ± 0.62 76.78 ± 5.34 72.13 ± 4.45 75.91 ± 3.68
L-meq 2.5 17.03 ± 0.49 2.23 ± 0.11 26.70 ± 1.84 8.24 ± 0.83 76.22 ± 4.73 65.17 ± 4.37 78.42 ± 2.90
L-meq 5.0 17.40 ± 0.69 2.19 ± 0.11 25.60 ± 1.51 8.19 ± 0.77 78.96 ± 4.37 64.39 ± 4.43 73.04 ± 3.11
L-meq 10 18.46 ± 0.59* 2.31 ± 0.12 24.40 ± 1.32 7.33 ± 0.52* 71.91 ± 4.62 62.74 ± 4.54 68.67 ± 3.55
Meq 10 17.19 ± 0.61 2.24 ± 0.13 24.30 ± 1.40 7.38 ± 0.66 75.30 ± 3.90 69.00 ± 3.48 75.39 ± 2.85
With alcohol
Plac 19.40 ± 0.72 2.43 ± 0.14 20.60 ± 1.24 5.38 ± 0.71 62.00 ± 6.12 64.48 ± 4.29 63.39 ± 3.81
L-meq 2.5 19.68 ± 0.71 2.42 ± 0.14 21.55 ± 1.14 4.14 ± 0.69 51.83 ± 5.06 55.43 ± 5.24 58.71 ± 3.80
L-meq 5.0 19.63 ± 0.76 2.46 ± 0.14 22.05 ± 1.26 4.86 ± 0.64 59.43 ± 5.53 61.22 ± 3.49 59.39 ± 4.16
L-meq 10 20.81 ± 0.79⟡ 2.52 ± 0.13 21.00 ± 1.15 3.90 ± 0.61 54.22 ± 5.36 59.17 ± 4.16 56.79 ± 4.07
Meq 10 20.57 ± 0.7⟡ 2.56 ± 0.12 21.65 ± 1.36 4.43 ± 0.73 55.39 ± 4.36 55.04 ± 3.03 56.94 ± 3.50
N. total 23 23 20 21 23 23 21
ANOVA
Treatment
df 4.88 4.88 4.76 4.80 4.88 4.88 4.80
F 4.30 0.85 0.99 2.52 0.95 1.27 1.79
p 0.007 NS NS 0.048 NS NS NS
Alcohol
df 1.22 1.22 1.19 1.20 1.22 1.22 1.20
F 55.56 24.49 52.42 204.48 32.9 6.12 24.28
p <0.001 <0.001 <0.001 <0.001 <0.001 0.021 <0.001
Treatment × alcohol
df 4.88 4.88 4.76 4.80 4.88 4.88 4.80
F 1.88 0.46 2.12 0.47 0.63 1.01 2.40
p NS NS NS NS NS NS NS
Significant treatment, alcohol or treatment × alcohol effects are indicated in bold (p < 0.05). Asterisks indicate: significant differences from placebo,
*p < 0.05 (after sdHBC); significant differences from placebo with alcohol, ⟡ p < 0.05 (after sdHBC)
Plac placebo, L-meq 2.5 l-mequitazine 2.5 mg, L-meq 5.0 l-mequitazine 5.0 mg, L-meq 10 l-mequitazine 10 mg, Meq 10 mequitazine 10 mg, NS not
significant, df degrees of freedom, sdHBC step-down Holm-Bonferroni correction
Fig. 2 Mean (±SE) standard
deviation of lateral position
(SDLP) for each treatment, alone
and with alcohol. Asterisks above
bars indicate: significant
differences from placebo,
*p < 0.05; significant differences
from placebo with alcohol,
⟡p < 0.05
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Mean (95 % CI) increase in SDLP after alcohol and l-
mequitazine 2.5, 5.0 and 10 mg, and mequitazine 10 mg com-
pared to alcohol alone were 0.29 (−0.90; +1.47), 0.22 (−0.67;
+1.13), 1.41 (+0.54; +2.28) and 1.17 (+0.38; +1.96).
Contrasts showed that the SDLP of both l-mequitazine
10 mg (p = 0.003) and mequitazine 10 mg (p = 0.006) in
combination with alcohol was significantly larger then alcohol
alone. Other drug-placebo contrasts were not significant.
For SDSP, a significant main effect of Alcohol was found
(F1.22 = 24.49, p < 0.001). Alcohol significantly increased
SDSP. Simple contrast analysis showed an overall mean
(95 % CI) increase in SDSP of 0.26 cm (+0.15; +0.37).
Memory
Mean (±SE) immediate and delayed recall score are shown in
Table 1. Analysis showed a significant main effect of Alcohol
on immediate recall scores (F1.19 = 52.42, p < 0.001), but no
effects of Treatment. Alcohol significantly reduced the num-
ber of words in all treatment conditions. Simple contrast anal-
ysis showed an overall mean (95 % CI) decrease of −4.27
(−5.50; −3.04) words.
For delayed recall, repeated measures analysis showed a sig-
nificant main effect of Treatment (F4.,80 = 2.52, p = 0.048), a
significantmain effect of Alcohol (F1.20 = 204.47, p < 0.001), but
no significant interaction effect of Treatment × Alcohol. Mean
(95 % CI) decrease in delayed recall scores after l-mequitazine
2.5, 5.0 and 10 mg, and mequitazine 10 mg alone compared to
placebo were −0.38 (+1.24; −2.00), −0.43 (+0.91; −1.77), −1.29
(−0.33; −2.24) and −1.24 (+0.12; − 2.60) items, respectively.
Contrast analysis showed that the effect of l-mequitazine 10 mg
alone was highly significant (p = 0.011) compared to placebo.
Other simple contrasts of drug-placebo conditions were not
significant.
Alcohol significantly reduced the number of words recalled
for delayed recall in all treatment conditions. Simple contrast
analysis showed an overall mean (95 % CI) decrease of −3.41
(−3.91; −2.91) words. Mean (95 % CI) decrease in delayed
recall score after alcohol and l-mequitazine 2.5, 5.0 and
10 mg, and mequitazine 10 mg compared to placebo with
alcohol were −1.24 (+0.16; −2.63), −1.05 (+0.77; −1.82),
−1.48 (−0.19; − 2.76) and −0.95 (+0.57; −2.48) items, respec-
tively. Contrasts between treatment combined with alcohol
and placebo in combination with alcohol showed no signifi-
cant drug-placebo contrasts.
Subjective evaluations
Analysis showed a significant effect of Alcohol for all subjec-
tive evaluations, but no effect of Treatment. After alcohol
consumption, participants rated their expected driving ability
and driving ability after completion of the driving test as sig-
nificantly worse (F1.22 = 32.76, p < 0.001 and F1.22 = 6.12,
p = 0.021, respectively). Alcohol significantly decreased alert-
ness (F1.20 = 24.28, p < 0.001). An overview of the subjective
evaluations is given in Table 1.
Adverse events
No serious adverse events were recorded during the study. The
most frequently reported adverse events were fatigue and
headache. Fatigue was mainly observed after treatment with
l-mequitazine 10 mg and mequitazine 10 mg. Headache was
mainly observed in the placebo condition. A summary of the
most commonly reported adverse events during all treatments
is given in Table 2.
Discussion
The current study was conducted to assess the effects of single
doses of l-mequitazine (2.5, 5.0 and 10 mg) and mequitazine
(10 mg), alone and in combination with alcohol, on actual
highway driving performance. Results indicate that l-
mequitazine, 2.5 and 5.0 mg, had no effect on highway driv-
ing performance. L-mequitazine 10 mg impaired highway
driving performance, as indicated by the significant 1.6-cm
increase of SDLP. Mequitazine 10 mg showed no effect on
highway driving performance. With regard to memory perfor-
mance, mequitazine 10 mg and l-mequitazine 2.5 and 5.0 mg
Table 2 Summary of total amount of adverse events after placebo, l-mequitazine 2.5 mg, l-mequitazine 5.0 mg, l-mequitazine 10 mg and mequitazine
10 mg as indicated by all participants who started treatment (n = 31). Only adverse events that are reported in more than 5 % of the cases are displayed
Placebo L-mequitazine 2.5 mg L-mequitazine 5.0 mg L-mequitazine 10 mg Mequitazine 10 mg
Adverse event N (%) N (%) N (%) N (%) N (%)
Fatigue 3 (9.7) 4 (12.9) 3 (9.7) 6 (19.4) 6 (19.4)
Headache 6 (19.4) 3 (9.7) 1 (3.2) 4 (12.9) 5 (16.1)
Nausea 3 (9.7) 2 (6.5) – 3 (9.7) –
Somnolence 1 (3.2) 3 (9.7) 2 (6.5) 1 (3.2) 3 (9.7)
Vomiting 1 (3.2) 2 (6.5) – – 1 (3.2)
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showed no effect. L-mequitazine 10 mg only impaired de-
layed recall. The difference in impairing effects on driving
performance and memory of equal doses (10 mg) of l-
mequitazine and mequitazine could be explained by l-
mequitazine’s higher affinity for histamine H1 receptors
(Gauthier et al., 2014; Renault and Le, 1983). Given that l-
mequitazine’s binding affinity for muscarine receptors is low
as compared to mequitazine, the effects cannot easily be ex-
plained by anticholinergic activity of these drugs (Clerc et al.,
2012; Heusler et al., 2015).
The clinical relevance of drug-induced performance chang-
es in the highway driving test is often determined by referring
to the relationship between blood alcohol concentration
(BAC) and SDLP (Louwerens et al., 1987), which showed
that an average SDLP increase of 2.4 cm is comparable to
driving under the influence of a BAC of 0.5 mg/ml. Acute
effects of l-mequitazine 10 mg caused a significant increase
in SDLP of 1.6 cm compared to placebo. Although this in-
crease is significant, this effect can be considered mild, given
that the SDLP increase between the alcohol-placebo and pla-
cebo treatment is 2.5 cm in the current study. The combination
of any treatment with alcohol led to significant performance
impairment. On average across all treatments, alcohol in-
creased SDLP by 2.63 cm, and decreased immediate and de-
layed recall by 4.27 words and 3.41 words, respectively. The
effects of alcohol and drugs did not interact significant-
ly. This indicates that, although the effects of alcohol
added to the effects of the drugs, the combined use
did not result in disproportionally increased impairment
(i.e. potentiation of effects). This lack of potentiation is
in line with previous studies assessing the combined
effect of alcohol and antihistamines (Vermeeren and
O’Hanlon, 1998; Vermeeren et al., 2002a).
Memory impairment was observed after administration
of l-mequitazine 10 mg alone on delayed recall. This
could be due to indirect effects of H1 receptor blockade
(Van Ruitenbeek et al., 2010), such as impaired concen-
tration and fatigue (Lieberman III, 2004; Penttilä et al.,
2005), since headache and fatigue were reported as ad-
verse events in the l-mequitazine condition. Lower dos-
ages of l-mequitazine did not impair immediate or delayed
recall, alone or with alcohol intake.
Participants were not aware of the driving impairment
caused by antihistamines, which is in line with previous stud-
ies (Theunissen et al., 2006; Vermeeren et al., 2002a).
Participants were, however, aware of the impairing effects of
alcohol on driving performance, which is also in line with a
previous study (Vermeeren et al., 2002b). For l-mequitazine
10 mg, participants were unable to predict their impairment
before driving and were unaware of the impairing effects after
test completion. Given that the effect of l-mequitazine 10 mg
was not clinically relevant, it can be assumed that the effect
was not large enough to be noticed by the participants.
The increase of SDLP (+0.33 cm) after mequitazine
10 mg alone was smaller than reported in previous
placebo-controlled studies, which showed a mean SDLP
increase of 2.5 cm (Theunissen et al., 2006) and 1.0 cm
(Theunissen et al., 2004). The smaller effect found in the
current study could be due to the exclusion of cytochrome
P450 CYP 2D6 slow metabolizers and due to the start of
the first driving test, i.e. 1 to 2 h after the tmax of
mequitazine. However, given the low prevalence of slow
metabolizers (10 % in the Caucasian population)
(Tamminga et al., 2001) and the long half-life (18 h) of
mequitazine, findings from this study might implicate that
the impairing effect of mequitazine 10 mg is, on average,
milder than previously reported.
In conclusion, l-mequitazine 10 mg produced mild driving
impairment, whereas l-mequitazine 2.5 and 5.0 mg show no
effects on driving. It should be noted that the absence of ef-
fects only reflects the average individual and that individual
differences should be taken into account. Alcohol (BAC of
0.5 mg/ml) led to significant driving impairment, but did not
potentiate the effects of l-mequitazine or mequitazine.
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